Professor of Clinical Medicine
Director, Hepatology Services, H.H. Chao Comprehensive Digestive Disease Center
|Natural history and new treatments of viral hepatitis B and C; natural history and chemoprevention of primary liver cancer|
|Research Support Award, Loma Linda University School of Medicine|
|Dr. Ke-Qin Hu is the Director of Hepatology Services and Associate Professor of Clinical Medicine at UCI School of Medicine. Dr. Hu received his medical education and training in Tongji Medical University, China. He become Board Certified in Internal Medicine in US after his residency at Huntington Memorial Hospital, Pasadena, and completed a fellowship in Hepatology at the USC Liver Unit. Dr. Hu has a long-standing research interest in both basic and clinical research of viral hepatitis B and C, and primary liver cancer. Dr. Hu’s current clinical research focuses on understanding how hepatitis B virus (HBV) and hepatitis C virus (HCV) infection is associated with fatty infiltrates in the liver and disease progression, and how viral hepatitis B and C are associated with liver cancer. As an active clinical investigator, Dr. Hu participates in several important clinical trials that tests new treatments for hepatitis B and C. Currently, his laboratory focuses on searching new chemoprevention of liver cancer. Dr. Hu has co-authored more than 100 research papers, book chapters, and review articles, including publications in Proc. Natl. Acad. Sci. USA, Journal of Clinical Investigation, and Hepatology. Dr. Hu serves as an associate editor for several medical journals.|
Hu K-Q, Song PH, Hao LJ. Immunohistochemical studies on hepatitis B markers in the liver tissue of patients with hepatocellular carcinoma. Inn Med 1987; 14:197-200.
Hu K-Q, Yu ZQ, Li FH, et al. Expression and clinical significance of pre-S1 and S2 proteins of HBV in sera of patients with chronic liver disease. Liver 1989; 9:146-152.
Hu K-Q, Hao LJ, Zhang YY, et al. Intrahepatic expression of pre-S1 and S2 proteins of hepatitis B virus and its possible relation to liver cell necrosis. Am J Gastroenterol 1989; 84:1538-1542.
Lopez-Cabrera M, Letovsky J, Hu K-Q, Siddiqui A. Multiple liver-specific factors bind to the hepatitis B virus core/pregenomic promoter: transactivation and repression by CCAAT/enhancer binding protein. Proc Natl Acad Sci USA 1990; 87:5069-5073.
Hu K-Q, Vierling JM, Siddiqui A. Transactivation of HLA DR gene by hepatitis B virus X gene product. Proc Natl Acad Sci USA 1990; 87:7140-7144.
Hu K-Q, Siddiqui A. Regulation of the hepatitis B virus gene expression by the enhancer element I. Virology 1991; 181:721-726.
Lopez-Cabrera M, Letovsky J, Hu K-Q, Siddiqui A. Transcriptional factor C/EBP binds to and transactivates the enhancer element II. Virology 1991; 183:825-829.
Hu K-Q, Yu CH, Vierling JM. Direct detection of circulating hepatitis C virus RNA using probes from the 5' untranslated region. J Clin Invest 1992; 89:2040-2045.
Hu K-Q, Yu C-H, Vierling JM. Upregulation of ICAM-1 by the X protein product of the hepatitis B virus. Proc Nat Acad Sci (USA) 1992; 89:11441-11445.
Hu K-Q, Yu C-H, Vierling JM. One-step polymerase chain reaction for detection of hepatitis C virus RNA. Hepatology 1993; 18:270-274.
Hu K-Q, Yu CH, and Vierling JM. Simultaneous detection of both hepatitis B virus DNA and hepatitis C virus RNA using a combined one-step polymerase chain reaction technique. Hepatology 1995; 21: 901-907.
Hu K-Q, Tong MJ. The long-term outcomes of patients with compensated HCV-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29:1311-1314.
Hu K-Q, Yu AS, Tiyyagura L, Redeker AG, Reynolds TB. Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit. Am J Gastroenterol 2001; 96:1581-1586.
Hu K-Q. Rationale and feasibility of chemoprevention of hepatocellular carcinoma by cyclooxygenase 2 (COX-2) inhibitors. J Lab Clin Med 2002; 139:234-243.
Hu K-Q. Occult HBV infection and its clinical implications. J Viral Hepatitis 2002; 9:245-254.
Hu K-Q, Yu C-H, Mineyama Y, et al. Inhibited proliferation of cyclooxygenase-2 (COX-2) expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor. International J Oncol, 2003 22:757-763.
Hill K, Hu K-Q, Cottrell A, Teichman S, Hillebrand DJ. Charcoal-based hemodiabsorption liver support for episodic type C hepatic encephalopathy. Am J Gastroenterol 2003; 98:2763-2770.
Hu K-Q. Cyclooxygenase 2 (COX2)-prostanoid pathway and liver diseases. Prostaglandins Leukotrienes and Essential Fatty Acids. 2003; 69:329-337.
Hu K-Q, Kyulo N, Esrailian E, Thompson K, Chase R, Hillebrand DJ, Runyon BA. Overweight and Obesity, Hepatic Steatosis, and Progression of Chronic Hepatitis C: A Large Cohort Study in the United States. J Hepatol 2004; 40:147-154.
Hu K-Q, HY Yang, YS Lin, Lindsay KL, Redeker AG. The clinical profile of chronic hepatitis C in a major county medical center outpatient setting in the United States. Int J Med Sci 2004; 1:92-100.
Hu K-Q, Kyulo N, Lim N, et al. Clinical Significance of Elevated Alpha Fetoprotein (AFP) in Patients with Chronic Hepatitis C, but Not Hepatocellular Carcinoma. Am J Gastroenterol 2004; 99:860-865.
Hu K-Q, Runyon BA. Ascites and Spontaneous Bacterial Peritonitis. In: Handbook of Liver Disease, Friedman LS, Keeffe EB (2nd eds). Churchill Livingstone, Philadephia, pp 149-163, 2004.
Hu K-Q, Runyon BA. Ascites and Its Complication. In: Advanced Therapy in Gastroenterology and Liver Diseases, 5th eds, by Bayless TM and Diehl AM. B.C. Decker Inc., Hamilton, London, pp 656-660, 2005.
Hu K-Q. A practical approach to management of chronic hepatitis B. International J Med Sci 2005; 2:27-35.
Srikureja W, Kyulo NL, Runyon BA, Hu K-Q. MELD score is a better prognostic model than Child-Turcotte-Pugh score or discriminant function score in patients with alcoholic hepatitis. J Hepatol 2005; 42: 700-706.
Hu K-Q, Lee SM, Hu SX, Xia VW, Hillebrand DJ, Kyulo NL. Clinical presentation of chronic hepatitis C in patients with end-stage renal disease and on hemodialysis versus those with normal renal function. Am J Gastroenterol 2005; 100:2010-2018.
Cui W, Yu C-H, Hu K-Q. In Vitro and In Vivo Effects and Mechanisms of Celecoxib-induced Growth Inhibition of Human HCC Cells. Clin Cancer Res 2005; 11:8213-8221.
Hu K-Q, Currie SL, Shen H, Cheung RC, Ho SB, Bini EJ, et al. Clinical Implications of Hepatic Steatosis in Patients with Chronic Hepatitis C: A Multicenter Study of U.S. Veterans. Dig Dis Sci 2007; 52; 570-578.
Esrailian E, Pantangco ER, Kyulo N, Hu K-Q, Runyon BA. Octreotide/midodrine therapy significantly improves survival in type 1 hepatorenal syndrome: analysis of 53 treated patients & 21 controls. Digest Dis Sci. 2007; 52:742-748.
Cui W, Hu SX, Tang Z, Hu K-Q. In vivo effects of cyclooxygenase-2 (COX-2) deletion on cellular signaling in HCC xenografts in nude mice. J Cancer Mol 2007; 3:49-54.
Lah J, Cui W, Hu K-Q. Inhibitory effects and mechanisms of silibinin on growth of human hepatoma cell lines. World J Gastroenterol 2007 13(40): 5299-5305.
Cui W, Hu SX, Tang Z-Y, Hu K-Q. In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice. Anti-Cancer Drugs 2008, 19:891–897.
Cui W, Gu F, Hu K-Q. Effects and mechanisms of silibinin on human Hepatocellular carcinoma xenografts in nude mice. World J Gastroenterol 2009; 15(16): 1943-1950.
Mellen JS, Xia VW, Hashemzadeh M, Imagawa D, Jamal M, Hoefs J, Hu K-Q. The clinical presentation of chronic hepatitis B virus (HBV) infection in Asian Americans: A single center retrospective study. J Clin Gastroeterol 2010; 44:364-370.
Cui W, Chen SL, Hu K-Q. Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. Am J Transl Res 2010; 2:95-104.
Hu K-Q, Schiff ER, Kowdley KV, Min AD, Shiffman ML, Lee WM, Goodman ZD, et al. Histologic evidence of active liver injury in chronic hepatitis B patients with normal range or minimally elevated alanine aminotransferase levels. J Clin Gastroeterol 2010; 44:510-516.
Harrison SA, Rossaro L, Hu K-Q, et al. Serum cholesterol and statin use predict virologica response to peginterferon and ribavirin therapy. Hepatology 2010; 52:864-874.
Muir AJ, Hu K-Q, Gordon SC, et al. Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. J Viral Hepatitis. 2010 Nov 25. doi: 10.1111/j.1365-2893.2010.01402.x. [Epub ahead of print].
Wong PY, Xia VW, Imagawa DK, Joefs J, Hu K-Q. Clinical presentation of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian-Americans. J immigrant minority health. 2010; doi 10.1007/s10903-010-9395-8.
Member of the American Assoc. for the Study of Liver Disease
Tongji Medical College, Huazhoung University of Science and Technology 2000—pres
|Research Center||UCI Chao Comprehensive Cancer Center|
|Link to this profile||http://www.faculty.uci.edu/profile.cfm?faculty_id=5193|